Equity Dilution for Academic Founders: How Ownership Shrinks Across Funding Rounds

When a university licenses inventor-founded technology into a new startup, it typically takes an initial equity stake as part or all of the consideration for the license — commonly somewhere in the low single digits to roughly 10% of the company, depending on the institution, the field, and how much of the value is instead captured through royalties or licensing fees. See Royalty vs. Equity Licensing Compensation for how that initial choice gets made, and the related backlog guide on the initial founder/university equity split covers how that starting percentage is negotiated at formation. This guide picks up from that starting point and stays narrowly focused on what happens next: how both the university’s stake and the founders’ stakes shrink, round by round, as the company raises seed, Series A, Series B, and later capital — the mechanics of dilution, how a cap table tracks it, what anti-dilution and pro-rata provisions do and don’t protect against, and what a technology transfer office (TTO) and a faculty founder should each understand and negotiate for as the company scales.

What dilution actually is

Dilution is the reduction in a shareholder’s percentage ownership that happens whenever a company issues new shares — not because existing shareholders sell or give anything away, but because the total number of shares outstanding grows while their own share count stays fixed. The basic arithmetic is simple: percentage ownership equals shares held divided by total shares outstanding. Every financing round, and every expansion of the employee option pool, increases the denominator.

A worked, illustrative walkthrough (not drawn from any real institution’s actual terms — round numbers chosen only to make the mechanic legible):

• At formation: a spinout issues 10,000,000 founder shares and grants the university 800,000 shares (8%) as part of its exclusive license consideration. Founders hold the remaining 9,200,000 shares (92%). Total shares outstanding: 10,000,000.
• Seed round: the company raises new capital by issuing 2,500,000 new preferred shares to seed investors. Total shares outstanding rise to 12,500,000. Without anyone selling a single share, the university’s stake is now 800,000 / 12,500,000 = 6.4%, and the founders’ combined stake is 9,200,000 / 12,500,000 = 73.6%. Both shrank in exact proportion to their pre-round ownership — that proportionality is the default outcome absent a specific protective provision (see below).
• Series A: the company issues a further 5,000,000 preferred shares. Total shares outstanding rise to 17,500,000. The university’s stake falls again, to 800,000 / 17,500,000 = 4.6%; the founders’ combined stake falls to 9,200,000 / 17,500,000 = 52.6%.

Nobody in this walkthrough did anything wrong, and nobody’s underlying number of shares changed. This is the ordinary, expected mechanism by which a growing company funds itself — an institution’s or founder’s proportional ownership declining across rounds is not, by itself, evidence of a bad deal. What matters is whether the company’s total value is growing faster than the ownership percentage is shrinking, and whether specific contractual terms shift how the dilution is distributed rather than letting it fall proportionally on everyone.

The cap table: what it tracks and why it matters here

A capitalization table (“cap table”) is the running ledger of who owns what: every class of stock (common, and one or more series of preferred), every option grant and the unallocated option pool, every convertible note or SAFE and the price and conditions under which it converts to equity, and the resulting fully diluted ownership percentage for each holder. For an academic spinout, the cap table typically has at least these categories from day one: founder common stock, an unallocated employee option pool, and the university’s stake (structured as either common stock or, less commonly, non-voting/founder-class shares tied to the license agreement).

Two mechanics on a cap table matter specifically for a university stake that a general startup cap-table primer usually skips:

• “Fully diluted” includes the option pool, whether or not it’s been granted yet. A newly-created or expanded option pool dilutes every existing holder, including the university, the same way a new investor’s shares do — this is a real, frequent source of dilution that has nothing to do with a funding round closing and is easy to miss if a TTO only tracks round-by-round percentage changes.
• Non-participating vs. participating preferred and liquidation preferences affect economic outcome, not the ownership percentage shown on the cap table. A university’s percentage can look stable while the actual dollar return it would receive on a sale or liquidation shifts materially, because preferred stockholders in later rounds are typically entitled to be paid back before common (and sometimes university) shares participate in the remaining proceeds. Reading the cap table’s ownership column alone, without also checking each series’ liquidation preference terms, understates how much economic value later rounds can absorb.

Anti-dilution provisions: what they actually protect against

“Anti-dilution” is a specific, narrower thing than the general dilution described above — it does not prevent the ordinary, proportional dilution that comes from a straightforward up round. It protects a specific class of preferred shareholder against one particular event: a down round, where new shares are issued at a lower price per share than that investor originally paid. The mechanism adjusts the earlier investor’s conversion price (the price at which their preferred stock converts to common), which increases the number of common shares they’re entitled to on conversion — protecting their economic stake at the expense of everyone else on the cap table, most directly the common stockholders (founders, and any university stake held as or convertible to common).

Two standard formulas, in order of how founder-friendly they are:

• Full ratchet resets the earlier investor’s conversion price all the way down to the new, lower round price — regardless of how many shares the new round actually issued. This is the most aggressive form and the most dilutive to everyone else; it is now uncommon in typical venture terms outside distressed or highly investor-favorable deals.
• Weighted average (the current market-standard form) adjusts the conversion price by a formula that accounts for both the price of the new round and how many shares it actually issued relative to shares already outstanding — a small down-round issuance moves the price only slightly; a large one moves it more. Weighted-average anti-dilution comes in broad-based (the calculation includes all fully diluted shares — common, preferred, and the option pool) and narrow-based (a smaller denominator that excludes some of those categories) variants. Broad-based weighted average produces a smaller, less dilutive adjustment and is the prevailing standard in current market practice; narrow-based gives the protected investor a stronger adjustment.

For an academic-founder spinout, this matters in two directions at once. If the university’s stake is held as preferred or carries an explicit anti-dilution term, it receives some protection against a down round the same way an institutional VC’s stake would. If the university’s stake is plain common stock with no anti-dilution provision — a common structure, since the university typically isn’t pricing its stake through a priced financing round the way an investor does — it has none, and a down round dilutes it exactly as much as it dilutes the founders, with no offsetting adjustment.

Pro-rata rights

A pro-rata right is a contractual right, not a protection against dilution automatically — it gives a shareholder the option to purchase enough new shares in a future round to maintain their existing percentage ownership, rather than being passively diluted by that round. It costs money to exercise: the holder has to actually put in new capital at the new round’s price to keep their percentage flat. For an institutional VC with follow-on reserves, exercising pro-rata rights in a company that’s performing well is routine. For a university, exercising a pro-rata right generally means writing an additional check from institutional funds into a private company’s next financing round — most technology transfer offices are not structured or funded to do this routinely, and institutional policy or state law may restrict it outright. In practice, a pro-rata right in the license or side-letter agreement gives the university the option to protect its percentage if it chooses and can fund it, but for most academic institutional stakes the more realistic value of the term is optionality and negotiating leverage, not an expectation that it will regularly be exercised.

What this means for the TTO negotiating the license

A technology transfer office negotiating equity as part of a license typically cannot prevent proportional dilution across future rounds — that is the ordinary cost of the company raising the capital it needs to grow, and resisting it is usually not a realistic or even desirable negotiating position, since a company that can’t raise follow-on capital is worth less to everyone, university included. What is realistic to negotiate for, and worth checking for in the license or in a separate stockholders’/side-letter agreement, includes:

• Anti-dilution protection matching what institutional investors receive — if the university’s stake can be structured as, or converted alongside, the same class of preferred stock a seed or Series A investor receives, it picks up the same down-round protection those investors negotiate for themselves, rather than sitting exposed as plain common.
• A pro-rata or participation right, even if the institution rarely expects to exercise it — it preserves the option and can be a real negotiating chip later (e.g., traded for other consideration) even when the university has no intention or ability to write a follow-on check.
• Information/inspection rights sufficient to actually see the cap table and financing terms as they change — a university that finds out about a down round or a large option pool expansion after the fact has no ability to evaluate whether its interests were considered.
• Anti-dilution carve-outs written into the license itself for the initial disclosure period, separate from any later stock-based protection — some institutions negotiate a floor (a minimum percentage, or a right to top up to a floor) that applies specifically before the first priced round, when the company is most likely to issue founder or advisor equity that could otherwise silently shrink the university’s position before any investor is even in the picture.
• Clarity on whether the university’s stake participates in later down-round dilution the same way founder common does, or whether it was negotiated with different treatment — this should be an explicit, written term, not an assumption on either side.

See Faculty Conflict of Interest in Startups for how a faculty founder’s dual role as inventor, researcher, and now equity holder is disclosed and managed — the same across-rounds dilution mechanics in this guide apply to the faculty founder’s personal stake exactly as they apply to the university’s, and a founder who also serves on the company’s board or as an officer typically has visibility into option pool and financing decisions that the university, as a passive shareholder, does not.

What this means for the faculty founder

A founder’s stake dilutes through the same proportional mechanism as the university’s, with three practical differences worth planning for:

• Founders usually negotiate the terms that dilute them — a founder sitting on the board or negotiating the term sheet has some influence over option-pool size, round size, and price, where a university with a passive stake typically does not. Understanding that influence is itself a reason to engage with the numbers rather than treat dilution as something that just happens.
• Vesting interacts with dilution. Founder shares are typically subject to a vesting schedule (commonly four years with a one-year cliff, a startup-market convention, not a university-specific rule); unvested shares can be repurchased if a founder leaves early, which is a separate mechanism from dilution but is often confused with it — a departing founder’s unvested shares typically return to the pool rather than being redistributed proportionally to remaining holders in the way a new financing round dilutes everyone.
• The option pool “shuffle.” Investors in a priced round frequently require the option pool to be expanded (and that expansion priced in) before the new money comes in, which means the dilution from the pool expansion falls on existing shareholders — largely the founders and the university — rather than being shared with the incoming investor. This is a standard, negotiable term sheet mechanic worth understanding precisely because it’s easy for a first-time academic founder to see only the investor’s headline valuation and ownership percentage and miss that the pool expansion is doing additional, separate dilutive work before the round even closes.

Reading a term sheet for dilution exposure

Both a TTO and a faculty founder reviewing a term sheet should be able to answer these questions before signing, since the headline valuation and investment amount alone don’t answer them:

• Is this a pre-money or post-money valuation, and is the new option pool being created inside the pre-money number (meaning existing holders absorb its full dilutive effect) or added on top post-money?
• What is the resulting fully diluted percentage for the university and for the founders after the round closes — not just the percentage the new investor is receiving?
• What anti-dilution formula (if any) applies to the new preferred, and does the university’s stake carry the same or a different protection?
• Does the university (or the founder) have a pro-rata right in this round, and is it realistic that either party could exercise it?
• What is the liquidation preference stack after this round — is it 1x non-participating (the current market standard for most rounds) or something more investor-favorable that could change what common and university shares actually receive on a sale even without changing the ownership percentage shown on the cap table?

Frequently asked questions

Does a university’s equity stake dilute the same way a founder’s does?

Mechanically, yes — both are existing shareholders whose percentage shrinks proportionally when new shares are issued, unless a specific contractual term (anti-dilution protection, a pro-rata right that’s actually exercised) changes that outcome for one party and not the other. The difference is practical, not mechanical: institutional investors and, less commonly, founders negotiate protective terms for themselves as a matter of course, while a university’s passive stake often carries no such protection unless the TTO specifically negotiated for it at the time of the license.

Can a university avoid dilution by negotiating a fixed percentage that never changes?

Not realistically, and most institutions don’t try. A fixed, non-dilutable percentage would make the company far less financeable, since every future investor would effectively be diluting themselves by a share that never shrinks — this is a request institutional investors would generally refuse to accept in a term sheet, and pushing for it can cost a spinout a round entirely. What is realistic is negotiating protective terms (anti-dilution matching what investors get, pro-rata rights, disclosure rights) that manage how the university’s stake dilutes, not whether it dilutes at all.

What happens to the university’s equity if the company later does a down round?

If the university’s stake carries no anti-dilution protection (common for a plain common-stock university position), it dilutes proportionally along with founder common stock, with no formula-based offset. If the stake was structured with, or contractually tied to, the same weighted-average protection the round’s preferred investors receive, the effective dilution is reduced by that formula the same way it is for those investors.

Is a bigger initial equity percentage always better for the university?

Not automatically. A larger initial stake that makes the company harder to finance, or that comes at the expense of cash royalties the institution might otherwise have negotiated, can produce a worse long-run outcome than a smaller stake in a well-capitalized, successfully financed company. The initial-split decision (covered separately, and in the choice between royalty and equity licensing structures) and the across-rounds dilution question in this guide are related but distinct: the first decides the starting position, this one covers what happens to that starting position as the company raises money.

Related CASRAI resources

• Royalty vs. Equity Licensing Compensation — how institutions choose between cash royalties, an equity stake, or a hybrid at the licensing stage.
• Funding Options for a University Spinout — SBIR/STTR, gap funds, licensing, and venture capital as sources of spinout financing.
• University Evergreen and Spinout Funds — how institutional evergreen funds reinvest returns from equity stakes back into new spinouts.
• Entrepreneurial Resources for University Spinouts and Faculty Founders.
• Faculty Conflict of Interest in Startups — disclosure and management of a faculty founder’s equity, board, and research-oversight roles.
• AUTM Technology Transfer Practice Manual.
• Technology Transfer: full topic overview.